"Nanobiotix has been pioneering nanomedicine for more than 17 years to bring a different approach to medicine.
Our therapeutic technologies are not based on biology or chemistry – they are based on physical principles at nanoscale. This paradigm shift has allowed us to discover novel approaches to improving treatment outcomes.
Our company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. With this approach, our ambition is to benefit millions of patients who receive radiation therapy by improving the efficiency of radiation in tumor cells without increasing the dose received by surrounding healthy tissues. We believe that radiotherapy combined with NBTXR3 can become a new standard of care in the treatment of cancer.
By viewing the human body through the lens of physics a new realm of possibilities has emerged."
Laurent Levy, CEO of Nanobiotix
Key Figures
European Market Approval (CE marking) in locally advanced Soft Tissue Sarcoma
clinical trials in several types of cancer
patents issued or in process of being issued
Clinical trials in 15 countries:
patients treated in the studies
physicians involved in clinical trials
million euros raised since its creation
Headquarters in Paris with 3 affiliates:
Paris, France
Cambridge, US
Madrid, Spain
